Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trialnews2025-12-15T16:10:23+00:00December 15th, 2025|Endpoints News|
Areteia Therapeutics to wind down after terminating Phase 3 asthma studiesnews2025-12-15T15:56:19+00:00December 15th, 2025|Endpoints News|
Immunome’s rare tumor drug passes Phase 3 test, could challenge Merck KGaAnews2025-12-15T15:34:08+00:00December 15th, 2025|Endpoints News|
Sanofi’s multiple sclerosis drug flunks Phase 3 trial, faces another PDUFA delaynews2025-12-15T12:19:41+00:00December 15th, 2025|Endpoints News|
Argenx cans thyroid eye disease trials of Vyvgart Hytrulonews2025-12-15T11:39:08+00:00December 15th, 2025|Endpoints News|
#SABCS25: Celcuity further details Phase 3 win; Relay’s PI3Kα inhibitor’s consistent performance; and morenews2025-12-12T16:20:58+00:00December 12th, 2025|Endpoints News|
Arcus, Gilead report Phase 3 TIGIT failure in upper GI cancersnews2025-12-12T15:59:53+00:00December 12th, 2025|Endpoints News|
Tenaya targets $60M offering after heart disease pipeline updatesnews2025-12-12T12:04:38+00:00December 12th, 2025|Endpoints News|
Umoja delays first readout for in vivo CAR-T therapynews2025-12-11T16:31:16+00:00December 11th, 2025|Endpoints News|
Rezolute crashes as its only drug fails in Phase 3news2025-12-11T16:20:43+00:00December 11th, 2025|Endpoints News|
